Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study

SIMPLE SUMMARY: Ibrutinib is an established standard of care in the first-line treatment of chronic lymphocytic leukemia. Since ibrutinib is given continuously, data on long-term treatment, outcomes, and safety are essential to inform clinical decision making. Here, we describe characteristics and o...

Descripción completa

Detalles Bibliográficos
Autores principales: Woyach, Jennifer A., Barr, Paul M., Kipps, Thomas J., Barrientos, Jacqueline C., Ahn, Inhye E., Ghia, Paolo, Girardi, Vincent, Hsu, Emily, Jermain, Mandy, Burger, Jan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857192/
https://www.ncbi.nlm.nih.gov/pubmed/36672456
http://dx.doi.org/10.3390/cancers15020507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857192/
https://www.ncbi.nlm.nih.gov/pubmed/36672456
http://dx.doi.org/10.3390/cancers15020507

Ejemplares similares